S3788-119
ReportedCLEAR LABELS Act
Mr. Armstrong’s recorded connection
Cosponsored this bill
-
Potential benefit to Pharmaceutical manufacturers
Lower risk
Summary unavailable
5. Confidentiality Nothing in the amendments made by this Act shall be construed as authorizing the Secretary of Health and Human Services to disclose any information that is a trade secret or confidential information subject to section 552(b)(4) of title 5, United States Code, or section 1905 of title 18, United States Code.
-
Potential benefit to Pharmaceutical manufacturers
Fewer compliance requirements
Summary unavailable
6. Effective date The amendments made by this Act shall apply to active pharmaceutical ingredients and finished drug products that are manufactured and packaged on or after the date that is 5 years after the date of enactment of this Act.
-
Unclear effects on Pharmaceutical manufacturers
No material effect identified
Summary unavailable
2. Require drug labeling to include original manufacturer and supply chain information Section 502(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(b)) is amended— by striking containing (1) the name and place of business of the manufacturer, packer, or distributor and inserting the following: “containing— (A)the name, place of business, and unique facility identifier of the manufact…